What We're Reading: Page 222
Industry reads hand-picked by our editors
Sep 16, 2019
-
The Wall Street Journal
The Startup That Manipulated Data to Get a Miracle Drug to Market
-
Reuters
U.S. court let Merck hide secrets about popular drug's risks
-
Bloomberg
Plaintiffs in Ohio Opioid Trial Ask for $8 Billion in Damages
-
The Sunday Times
Neil Woodford’s Benevolent AI sees valuation slashed
Sep 13, 2019
Sep 12, 2019
-
Bloomberg
How Carcinogen-Tainted Generic Drug Valsartan Got Past the FDA
-
Associated Press
Some states say they'll keep fighting Purdue Pharma in court
-
STAT
In a CRISPR first, therapy aiming to cure HIV patient appears safe
-
The New York Times
Why Aren’t There Better Cancer Drugs? Scientists May Have Picked the Wrong Targets
Sep 11, 2019
Sep 10, 2019
Sep 09, 2019
-
Los Angeles Times
An FDA insider's view of where medical innovation falls short
-
ProPublica
Data Touted by OxyContin Maker to Fight Lawsuits Doesn't Tell the Whole Story
-
The New York Times
The challenge of identifying Sjogren's syndrome
-
The Dallas Morning News
When opioids go missing, hospitals are supposed to alert the DEA. That didn’t happen at UT Southwestern
Sep 06, 2019
-
Reuters
Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect'
-
The Wall Street Journal
A Turn for the Worse for Biotech Stocks
-
C&EN
Gut bacteria feast on the pills we pop
Previous
